CSTA plays a role in osteoclast formation and bone resorption by mediating the DAP12/TREM2 pathway.

[1]  K. Izumi,et al.  Testosterone and Bone Health in Men: A Narrative Review , 2021, Journal of clinical medicine.

[2]  E. Lespessailles,et al.  Bariatric Surgery and Osteoporosis , 2021, Calcified Tissue International.

[3]  Qiangqiang Li,et al.  Role of sirtuins in bone biology: Potential implications for novel therapeutic strategies for osteoporosis , 2021, Aging cell.

[4]  W. Högler,et al.  Mechanisms of Bone Fragility: From Osteogenesis Imperfecta to Secondary Osteoporosis , 2021, International journal of molecular sciences.

[5]  H. Takayanagi.  RANKL as the master regulator of osteoclast differentiation , 2021, Journal of Bone and Mineral Metabolism.

[6]  Zuolin Wang,et al.  Trem2 mediated Syk-dependent ROS amplification is essential for osteoclastogenesis in periodontitis microenvironment , 2020, Redox biology.

[7]  H. Neumann,et al.  A reporter cell system for the triggering receptor expressed on myeloid cells 2 reveals differential effects of disease‐associated variants on receptor signaling and activation by antibodies against the stalk region , 2020, Glia.

[8]  X. Cui,et al.  Mechanism of TREM2/DAP12 complex affecting β-amyloid plaque deposition in Alzheimer's disease modeled mice through mediating inflammatory response , 2020, Brain Research Bulletin.

[9]  Haiyoung Jung,et al.  Molecular Mechanisms and Emerging Therapeutics for Osteoporosis , 2020, International journal of molecular sciences.

[10]  B. Grigolo,et al.  Learning from Monocyte-Macrophage Fusion and Multinucleation: Potential Therapeutic Targets for Osteoporosis and Rheumatoid Arthritis , 2020, International journal of molecular sciences.

[11]  I. Lambrinoudaki,et al.  Estrogen and bones after menopause: a reappraisal of data and future perspectives , 2020, Hormones.

[12]  Jung-Min Kim,et al.  Bone-Targeting AAV-Mediated Gene Silencing in Osteoclasts for Osteoporosis Therapy , 2020, Molecular therapy. Methods & clinical development.

[13]  A. Qian,et al.  F2r negatively regulates osteoclastogenesis through inhibiting the Akt and NFκB signaling pathways , 2020, International journal of biological sciences.

[14]  A. Rezapour,et al.  Economic burden of osteoporosis in the world: A systematic review , 2020, Medical journal of the Islamic Republic of Iran.

[15]  Jennifer J Kelly,et al.  Combination therapies in the treatment of osteoporosis. , 2019, Current opinion in endocrinology, diabetes, and obesity.

[16]  M. Kverka,et al.  Update on Menopausal Hormone Therapy for Fracture Prevention , 2019, Current Osteoporosis Reports.

[17]  Z. Ouyang,et al.  Glycyrrhizic acid suppresses osteoclast differentiation and postmenopausal osteoporosis by modulating the NF-κB, ERK, and JNK signaling pathways. , 2019, European journal of pharmacology.

[18]  A. Qian,et al.  Microtubule actin crosslinking factor 1 (MACF1) knockdown inhibits RANKL-induced osteoclastogenesis via Akt/GSK3β/NFATc1 signalling pathway , 2019, Molecular and Cellular Endocrinology.

[19]  Ajay Kumar,et al.  Interplay of ERα binding and DNA methylation in the intron-2 determines the expression and estrogen regulation of cystatin A in breast cancer cells , 2019, Molecular and Cellular Endocrinology.

[20]  Anna Teti,et al.  Immune Function and Diversity of Osteoclasts in Normal and Pathological Conditions , 2019, Front. Immunol..

[21]  F. Uhle,et al.  From macrophage to osteoclast – How metabolism determines function and activity , 2018, Cytokine.

[22]  S. Inoue,et al.  The Sealing Zone in Osteoclasts: A Self-Organized Structure on the Bone , 2018, International journal of molecular sciences.

[23]  Junjie Xing,et al.  DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  P. Katsimbri.  The biology of normal bone remodelling , 2017, European journal of cancer care.

[25]  Soo Young Lee,et al.  Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation , 2017, Molecules and cells.

[26]  Huaxi Xu,et al.  TREM2/DAP12 Complex Regulates Inflammatory Responses in Microglia via the JNK Signaling Pathway , 2017, Front. Aging Neurosci..

[27]  Junfeng Cai,et al.  Identification of crucial genes related to postmenopausal osteoporosis using gene expression profiling , 2016, Aging Clinical and Experimental Research.

[28]  M. B. Humphrey,et al.  A Comprehensive Review of Immunoreceptor Regulation of Osteoclasts , 2016, Clinical Reviews in Allergy & Immunology.

[29]  B. Komm,et al.  The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women , 2015, Expert review of clinical pharmacology.

[30]  Ju-Young Kim,et al.  Massive elimination of multinucleated osteoclasts by eupatilin is due to dual inhibition of transcription and cytoskeletal rearrangement , 2015, Bone reports.

[31]  M. Kassem,et al.  Inhibiting actin depolymerization enhances osteoblast differentiation and bone formation in human stromal stem cells. , 2015, Stem cell research.

[32]  L. Yao,et al.  DDR2 (discoidin domain receptor 2) suppresses osteoclastogenesis and is a potential therapeutic target in osteoporosis , 2015, Science Signaling.

[33]  M. Mazzorana,et al.  DAP12 Overexpression Induces Osteopenia and Impaired Early Hematopoiesis , 2013, PloS one.

[34]  M. Jurkowska,et al.  Structure, expression pattern and biological activity of molecular complex TREM-2/DAP12. , 2013, Human immunology.

[35]  J. Cauley,et al.  Changes in bone resorption across the menopause transition: effects of reproductive hormones, body size, and ethnicity. , 2013, The Journal of clinical endocrinology and metabolism.

[36]  R. Baron,et al.  Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. , 2013, The Journal of clinical investigation.

[37]  D. Kelsell,et al.  Mutations in CSTA, encoding Cystatin A, underlie exfoliative ichthyosis and reveal a role for this protease inhibitor in cell-cell adhesion. , 2011, American journal of human genetics.

[38]  H. Takayanagi,et al.  Ca2+‐NFATc1 signaling is an essential axis of osteoclast differentiation , 2009, Immunological reviews.

[39]  F. Ross.  M‐CSF, c‐Fms, and Signaling in Osteoclasts and their Precursors , 2006, Annals of the New York Academy of Sciences.

[40]  L. Lanier,et al.  TREM2, a DAP12‐Associated Receptor, Regulates Osteoclast Differentiation and Function , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[41]  A. Mócsai,et al.  The immunomodulatory adapter proteins DAP12 and Fc receptor γ-chain (FcRγ) regulate development of functional osteoclasts through the Syk tyrosine kinase , 2004 .

[42]  C. Buonsanti,et al.  Impaired Differentiation of Osteoclasts in TREM-2–deficient Individuals , 2003, The Journal of experimental medicine.

[43]  L. Peltonen,et al.  DAP12/TREM2 Deficiency Results in Impaired Osteoclast Differentiation and Osteoporotic Features , 2003, The Journal of experimental medicine.

[44]  L. Peltonen,et al.  Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. , 2002, American journal of human genetics.

[45]  G. V. D. Van der Weijden,et al.  Cystatin A in gingival crevicular fluid of periodontal patients. , 1997, Journal of periodontal research.

[46]  H. Bernstein,et al.  Cystatin a-like immunoreactivity is widely distributed in human brain and accumulates in neuritic plaques of alzheimer disease subjects , 1994, Brain Research Bulletin.